title: Intralesional administration of rituximab for treatment of CD20 positive orbital lymphoma: safety and efficacy evaluation.
abstract: B-cell lymphomas constitute the most frequent malignant neoplasm of the ocular adnexal, often presenting with localized disease. Five patients with primary localized CD20 positive B cell non Hodgkin ocular adnexal lymphomas received intralesional rituximab at the dose of 5mg once a week for one month, followed by 10mg weekly in case of incomplete response. Four of five patients obtained regression of symptoms and 2 of them showed complete response. No patients experienced side effects besides pain on the site of the injection. Local treatment with Rituximab for OAL is a safe and useful first-line therapeutic option.
authors.affiliation: Department of Hematology, Catholic University of the Sacred Hearth, Largo A Gemelli 8, 00168 Rome, Italy. l.laurenti@rm.unicatt.it
authors.forename: Luca
authors.initials: L
authors.lastname: Laurenti
authors.forename: Laura
authors.initials: L
authors.lastname: De Padua
authors.forename: Remo
authors.initials: R
authors.lastname: Battendieri
authors.forename: Michela
authors.initials: M
authors.lastname: Tarnani
authors.forename: Simona
authors.initials: S
authors.lastname: Sica
authors.forename: Maria Antonietta
authors.initials: MA
authors.lastname: Blasi
authors.forename: Gustavo
authors.initials: G
authors.lastname: Savino
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Leone
mesh_terms: D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage* / Q000009:adverse effects; D018951:Antigens, CD20 / Q000276:immunology / Q000378:metabolism; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D015552:Injections, Intralesional; D008223:Lymphoma; D008228:Lymphoma, Non-Hodgkin / Q000000981:diagnostic imaging / Q000188:drug therapy; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009918:Orbital Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy; D010865:Pilot Projects; D011859:Radiography; D012074:Remission Induction; D000069283:Rituximab; D016896:Treatment Outcome
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D000069283:Rituximab